The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Roche
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
ELLA01-1: A study to determine the utility of TP53 mutations as a prognostic biomarker in adenoid cystic carcinoma.
 
Robert Metcalf
No Relationships to Disclose
 
Khaireah Mubarak
No Relationships to Disclose
 
Becky Bola
No Relationships to Disclose
 
Samuel Rack
No Relationships to Disclose
 
David Morgan
No Relationships to Disclose
 
Tracy Hussell
Research Funding - GlaxoSmithKline K.K. (Inst)
 
Andrew Wallace
No Relationships to Disclose
 
Guy Betts
No Relationships to Disclose
 
Kevin Joseph Harrington
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Replimune (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst)